188 related articles for article (PubMed ID: 22773551)
1. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Heinemann V; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler TC; von Weikersthal LF; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Rubanov O; Baake G; Höhler T; Ko YD; Jung A; Neugebauer S; Boeck S
Gut; 2013 May; 62(5):751-9. PubMed ID: 22773551
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W;
J Clin Oncol; 2007 May; 25(15):1960-6. PubMed ID: 17452677
[TBL] [Abstract][Full Text] [Related]
4. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Middleton G; Silcocks P; Cox T; Valle J; Wadsley J; Propper D; Coxon F; Ross P; Madhusudan S; Roques T; Cunningham D; Falk S; Wadd N; Harrison M; Corrie P; Iveson T; Robinson A; McAdam K; Eatock M; Evans J; Archer C; Hickish T; Garcia-Alonso A; Nicolson M; Steward W; Anthoney A; Greenhalf W; Shaw V; Costello E; Naisbitt D; Rawcliffe C; Nanson G; Neoptolemos J
Lancet Oncol; 2014 Jul; 15(8):829-40. PubMed ID: 24954781
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Yang ZY; Yuan JQ; Di MY; Zheng DY; Chen JZ; Ding H; Wu XY; Huang YF; Mao C; Tang JL
PLoS One; 2013; 8(3):e57528. PubMed ID: 23472089
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Wang Y; Hu GF; Zhang QQ; Tang N; Guo J; Liu LY; Han X; Wang X; Wang ZH
Drug Des Devel Ther; 2016; 10():1961-72. PubMed ID: 27358556
[TBL] [Abstract][Full Text] [Related]
10. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.
Weiss L; Fischer LE; Heinemann V; Gieseler F; Hoehler T; Mayerle J; Quietzsch D; Reinacher-Schick A; Schenk M; Seipelt G; Siveke JT; Stahl M; Kaiser U; Waldschmidt DT; Dorman K; Zhang D; Westphalen CB; Boeck S; Haas M
ESMO Open; 2024 Apr; 9(4):102944. PubMed ID: 38503144
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Monti DA; Mitchell E; Bazzan AJ; Littman S; Zabrecky G; Yeo CJ; Pillai MV; Newberg AB; Deshmukh S; Levine M
PLoS One; 2012; 7(1):e29794. PubMed ID: 22272248
[TBL] [Abstract][Full Text] [Related]
12. Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Ying JE; Zhu LM; Liu BX
World J Gastroenterol; 2012 Feb; 18(8):736-45. PubMed ID: 22371633
[TBL] [Abstract][Full Text] [Related]
13. Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
Hurt CN; Mukherjee S; Bridgewater J; Falk S; Crosby T; McDonald A; Joseph G; Staffurth J; Abrams RA; Blazeby JM; Bridges S; Dutton P; Griffiths G; Maughan T; Johnson C
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):810-8. PubMed ID: 26530749
[TBL] [Abstract][Full Text] [Related]
14. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.
Annels NE; Shaw VE; Gabitass RF; Billingham L; Corrie P; Eatock M; Valle J; Smith D; Wadsley J; Cunningham D; Pandha H; Neoptolemos JP; Middleton G
Cancer Immunol Immunother; 2014 Feb; 63(2):175-83. PubMed ID: 24292263
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial.
Jo JH; Kim YT; Choi HS; Kim HG; Lee HS; Choi YW; Kim DU; Lee KH; Kim EJ; Han JH; Lee SO; Park CH; Choi EK; Kim JW; Cho JY; Lee WJ; Moon HR; Park MS; Kim S; Song SY
Br J Cancer; 2024 Jan; 130(1):43-52. PubMed ID: 37903909
[TBL] [Abstract][Full Text] [Related]
16. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
Ko AH; Bekaii-Saab T; Van Ziffle J; Mirzoeva OM; Joseph NM; Talasaz A; Kuhn P; Tempero MA; Collisson EA; Kelley RK; Venook AP; Dito E; Ong A; Ziyeh S; Courtin R; Linetskaya R; Tahiri S; Korn WM
Clin Cancer Res; 2016 Jan; 22(1):61-8. PubMed ID: 26251290
[TBL] [Abstract][Full Text] [Related]
17. Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report.
Connell CM; Brais R; Whitaker H; Upponi S; Beh I; Risdall J; Corrie P; Janowitz T; Jodrell DI
BMC Cancer; 2020 Jan; 20(1):38. PubMed ID: 31941506
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W
J Clin Oncol; 2023 Oct; 41(30):4714-4720. PubMed ID: 37847995
[TBL] [Abstract][Full Text] [Related]
19. Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
Middleton G; Greenhalf W; Costello E; Shaw V; Cox T; Ghaneh P; Palmer DH; Neoptolemos JP
Br J Cancer; 2016 Mar; 114(5):510-8. PubMed ID: 26931369
[TBL] [Abstract][Full Text] [Related]
20. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
Rahma OE; Duffy A; Liewehr DJ; Steinberg SM; Greten TF
Ann Oncol; 2013 Aug; 24(8):1972-9. PubMed ID: 23670093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
